三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
替尔泊肽高剂量组恶心、腹泻比例超过20%
替尔泊肽高剂量组恶心、腹泻比例超过20%
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:145KB
图片尺寸:1169*941
同报告图片
/
4
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
所属报告:
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117(38页).pdf
打包全文图表
相关数据
高剂量玛仕度肽减重效率优于司美格鲁肽及替尔泊肽
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
收藏
行业数据
2024-08-15
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
了其在整个试验中均优于 Wegovy。主要重点方面,72 周后 Zepbound 组受试者平均减重 20.2%,而 Wegovy 组受试者平均减重 13.7%。
行业数据
原图定位
当前图表所属:
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117(38页).pdf
2026年GLP-1行业报告:产品迭代驱动扩容,多靶点与口服剂型重塑格局
【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117
GLP-1类减重药物1-3年维持率约32%/15%/8%
1Q23-2Q25,司美/替尔泊肽减重适应症销售额占比提升至37%
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》